Time to glaucoma progression detection by optical coherence tomography and visual field in glaucoma individuals of African descent.

To examine the time to glaucoma progression detection by retinal nerve fiber layer thickness (RNFLT) and visual field (VF) among African descent (AD) individuals. Retrospective cohort study. Setting: Multi-center. We included AD glaucoma eyes from DIGS/ADAGES with ≥2-year/5-visits of optic nerve head RNFLT and 24-2 VF examinations. Intervention or Observation Procedure: Rates of VF mean deviation (MD) and RNFLT worsening were analyzed using linear mixed-effects models, and longitudinal data was simulated using the variability estimates. The simulated time to detect trend-based glaucoma progression was assessed with assumed rates of VF MD and RNFLT change derived from the cohort (25 We included 184 eyes from 128 AD subjects (mean baseline age: 63.4 years; VF MD: -4.2 dB, RNFLT: 80.2 µm). The p25, median, mean and p75 rates of change were -0.43, -1.01, -1.15 and -1.64 µm/year for RNFLT, and 0.00, -0.21, -0.30 and -0.51 dB/year for VF MD, respectively. Compared to VF MD, RNFLT showed an overall shorter mean time to progression detection (time difference: 0.4-1.7 years), with the mean rates showing the largest difference (RNFLT: 5.2 years vs. VF MD: 6.9 years). Similarly, we found an overall shorter time to detect RNFLT progression, compared to that of VF MD progression, in mild glaucoma eyes (≥1 year earlier) and in moderate-advanced glaucoma eyes (∼0.5 year earlier). Computer simulation showed potentially shorter time to detect RNFLT progression than VF MD progression in AD eyes. Our findings support the importance of using RNFLT to detect progressive glaucoma in AD individuals.

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Funding: This work is supported by National Institutes of Health/National Eye Institute Grants R01EY029058, R01EY011008, R01EY019869, R01EY027510, R01EY026574, R01EY018926, R01EY034148, Core grant P30EY022589; University of California Tobacco Related Disease Research Program grant #T31IP1511; and an unrestricted grant from Research to Prevent Blindness (New York, NY). The sponsor or funding organization had no role in the design or conduct of this research. Financial Disclosure: Sasan Moghimi reported grants from the National Eye Institute. Takashi Nishida is a consultant for Topcon. Jeffrey M. Liebmann is a consultant to Alcon, Allergan, Thea, Genetech, AdvanceSight, and Carl Zeiss Meditec. Massimo A. Fazio reported grants from the National Eye Institute; grants from Heidelberg Engineering and Topcon; nonfinancial support from Wolfram Research. Christopher A. Girkin reported research support from Heidelberg Engineering and Topcon. Linda Zangwill reported grants from the National Institutes of Health, National Eye Institute; grants from Heidelberg Engineering and nonfinancial support from Carl Zeiss Meditec, Optovue, Heidelberg Engineering, and Topcon; and patents from Carl Zeiss Meditec and AiSight Health; co-founder and board member AiSight Health. Linda Zangwill is a consultant of Abbvie and Topcon Medical Systems. Robert N. Weinreb is a consultant of Abbvie, Alcon, Allergan, Amydis, Editas, Equinox, Eyenovia, Iantrek, IOPtic, Implandata, iSTAR Medical, Nicox, Santen, Ten Point and Topcon. He receives grants from the National Eye Institute and National Institute of Minority Health Disparities and Research to Prevent Blindness. He reports patents licensed by UCSD to Toromedes and Carl Zeiss Meditec from UCSD; founder of Toromedes; all outside the submitted work. No other disclosures were reported.